Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 DOTATOC in Non-GEP-NETs
NCT04276597Phase 2Withdrawn
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177-edotreotide in pulmonary neuroendocrine tumor, pheochromocytoma, Paraganglioma (PGL), thymic neuroendocrine tumor (tNEN), Neuroendocrine Neoplasm (NEN), sponsored by Excel Diagnostics and Nuclear Oncology Center. Planned start Mar 2020; status: withdrawn.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
pulmonary neuroendocrine tumorpheochromocytomaParaganglioma (PGL)thymic neuroendocrine tumor (tNEN)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04276597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276597.